Select Page

Cytokeratins Could Aid Early Detection of Hepatocellular Carcinoma in Patients with HCV
“A new model based on cytokeratin 18 (CK18), cytokeratin 19 (CK19), albumin, platelet count, and α-fetoprotein (AFP) may offer a refined approach for detecting hepatocellular carcinoma (HCC) in patients with hepatitis C virus (HCV).”

Glecaprevir, Pibrentasvir Effective for HCV Regardless of Cirrhosis, Treatment Period
“Findings from a recent study suggest glecaprevir/pibrentasvir therapy is effective for patients with cirrhosis with chronic hepatitis C virus (HCV) infection, regardless of whether they undergo an 8 or 12-week treatment period.”

Increased Social Support Linked to HCV Status Awareness, Treatment Uptake
“Individuals with a history of injection drug use who have a robust social support system are more likely to seek care for hepatitis C virus (HCV) infection, according to study results published in Open Forum Infectious Diseases.”

HCV Genotype, First-Line Therapy Do Not Impact Salvage Therapy Response
“Combination sofosbuvir, velpatasvir, and voxilaprevir (SOF/VEL/VOX) is a safe and effective rescue therapy for patients with hepatitis C virus (HCV) who previously failed sofosbuvir/velpatasvir (SOF/VEL) and glecaprevir/pibrentasvir (GLE/PIB), according to findings from a recent study.”

Free Hepatitis C Treatment Program Reduces Community Viral Load
“In a rural Kentucky county, free medical care and direct-acting antiviral treatment for people with hepatitis C greatly reduced the proportion of people with hepatitis C virus (HCV) viremia, or detectable viral load, researchers reported at The Liver Meeting 2023.”

Unstable Housing May Be a Barrier to HCV Treatment Among People Who Inject Drugs
“Unstable housing may lead to poorer treatment outcomes among people who inject drugs (PWID) with hepatitis C virus (HCV) versus those with stable housing, according to findings from a recent systematic review and meta-analysis.”